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Abstract: Dyslipidemia is a primary, critical risk factor for cardiovascular disease. Therefore,
evaluating the trends in lipid profiles is crucial for the development of health policies and programs.
We studied trends in lipid profiles in Korean adults over an 11-year period according to the use
of lipid-lowering medications through age-specific analysis. A total of 73,890 participants were
included in the Korean National Health and Nutrition Examination Survey III (2005)-VI (2013–2015).
The proportion of participants on lipid-lowering medications has increased. This trend was apparent
in age groups of over 40 years in both men and women. Lipid-lowering medications successfully
reduced mean total cholesterol (TC), but there was no favorable trend in TC in participants not taking
lipid-lowering medication in both men and women. Unlike men, triglyceride and non-high-density
lipoprotein cholesterol (HDL) decreased in women without lipid-lowering medications. In age-specific
hypercholesterolemia, the prevalence of hypercholesterolemia significantly increased in the age
groups of 30–59 and 30–49 years in men and women without lipid-lowering medications, respectively.
Meanwhile, mean HDL-C levels increased over the 11-year period regardless of lipid-lowering drug
use in both men and women. These analyses identified an upward trend in TC and HDL-C over the
11-year period.
Keywords: total cholesterol; triglyceride; high-density lipoprotein cholesterol; dyslipidemia; prevalence
1. Introduction
According to the 2017 statistical update of the American Heart Association, the number of deaths
from cardiovascular disease (CVD) has been decreasing since 2004 [1]. However, CVD remains the
leading cause of total mortality worldwide, accounting for 30% of all global deaths [1,2]. CVD is
responsible for an immense socioeconomic burden on patients and society in general. There are several
methods to prevent CVD, including smoking cessation, increased physical activity, and adoption
of a healthy diet [3,4]. Dyslipidemia, i.e., abnormal lipid levels in the blood, is considered one of
the most important modifiable risk factors of CVD [5]. One recent study found that even moderate
hyperlipidemia increases one’s risk of coronary heart disease (CHD) later in life, depending on
the length of exposure [6]. Therefore, active screening and treatment of dyslipidemia are the
first steps in prevention of CVD. Many countries have established public health programs to
address dyslipidemia [7]. These efforts have successfully led to a decrease in the prevalence of
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hypercholesterolemia in 1999–2000 and 2013–2014 in the United States [8]. In Europe, mean total
cholesterol (TC) levels have also declined over the last 30 years [9]. However, these analyses were only
based on serum cholesterol concentrations, without considering whether participants were prescribed
lipid-lowering drugs. Meanwhile, the prevalence of hypercholesterolemia continues to increase in
Japanese and Turkish populations [10,11], concurrently with a trend of rising TC and low-density
lipoprotein cholesterol (LDL-C) levels in China [12]. One Korean study reported that the prevalence
of dyslipidemia is declining [13]; however, there is a need for more recent data with regard to lipid
profiles to establish appropriate public health policies. There is also a need for studies that address the
use of lipid-lowering drugs.
Therefore, we aimed to investigate the 11-year trends regarding changes in the lipid profile of
participants after stratifying for lipid-lowering medication use by age-specific analysis.
2. Materials and Methods
2.1. Study Subjects
The Korean National Health and Nutrition Examination Survey (KNHANES), a cross-sectional
national representative survey, was conducted by the Korea Centers for Disease Control and Prevention
(KCDC) based on the National Health Promotion Act. This survey uses complex and multistep
probability sample design to obtain a representative sample of the civilian, non-institutionalized
Korean population. The primary sample unit (PSU) is selected from geographical data from the
entire country, and 20 final target households were sampled for each PSU using systematic sampling.
Approximately 10,000 samples were collected for approximately 192 PSUs per year. Statistical weights
were assigned to each participant to represent the entire Korean population. This survey is composed
of three component surveys (a health interview, health examination, and nutrition survey) in the six
phases of KNHANES I (1998), II (2001), III (2005), IV (2007–2009), V (2010–2012), and VI (2013–2015).
These data provide a variety of information regarding health status, health behavior, socioeconomic
demographics, and laboratory tests. Trained interviewers conducted face-to-face interviews with
participants. Participants could refuse to participate in this survey, and a written agreement was
obtained by participants upon consent [14]. Detailed information about KNHANES has been published
in a previous study by the KCDC [14,15].
Due to laboratory data inaccuracies in the KNHANES I and II surveys, we used data from
the KNHANES III (2005), IV (2007–2009), V (2010–2012), and VI (2013–2015). Of the total 107,498
participants from the KNHANES III–VI surveys, we excluded individuals meeting any of the following
criteria: <20 years of age, patients who had not fasted for at least 8 hours prior to sampling,
and patients who had missing values on a health interview survey regarding dyslipidemia. After these
exclusions, 73,935 participants (32,260 men and 41,675 women) were ultimately included in this study.
The Institutional Review Board (IRB) of the KCDC approved this study.
The ethical approval code number of Institutional Review Board (IRB) of the Korea Centers for
Disease Control and Prevention (KCDC) is 2013-12EXP-03-5C.
2.2. Anthropometric and Laboratory Measurements
Well-trained staff obtained anthropometric measurements following standard procedures.
Body weight was measured to the nearest 0.1 kg, and height and waist circumference (WC) were
measured to the nearest 0.1 cm while the participants were wearing light clothing and no shoes.
The body mass index (BMI) was calculated as the ratio of weight (kg) to height (m2) (kg/m2). Systolic
and diastolic blood pressure (SBP and DBP, respectively) were obtained using a standard mercury
sphygmomanometer with participants in a seated position. Blood samples were collected from an
antecubital vein in the morning after an overnight fast. The serum levels of TC, high-density lipoprotein
cholesterol (HDL-C), triglyceride (TG), and fasting plasma glucose (FPG) were measured enzymatically
using an Advia 1650/2400 (Siemens, New York, NY, USA) in the 2005 and 2007 surveys, and a Hitachi
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Automatic Analyzer 7600/7600-210 (Hitachi, Tokyo, Japan) in the 2008, 2010, 2011, 2012, 2013, 2014,
and 2015 surveys.
2.3. Lipid Profiles, and Related Variables
According to the criteria of the National Cholesterol Education Program Adult Treatment Panel III
(NCEP-ATP III) [16], hypercholesterolemia is defined as serum TC≥ 240 mg/dL; hypertriglyceridemia is
defined as TG ≥ 150 mg/dL; and hypo-HDL-cholesterolemia is defined as serum HDL-C < 40 mg/dL in
men and < 50 mg/dL in women. Non-HDL cholesterol was calculated by subtracting the HDL-C value
from a TC value [17]. Education duration was divided into four groups: <6 years, 6–9 years, 9–12 years,
and ≥12 years. Occupational status was categorized as manual work (clerk, service, and sales workers,
skilled agricultural, forestry and fishery workers, and persons who operate or assemble equipment
or machines), office work (general managers, government administrators, professionals, and simple
office worker), or other (unemployed persons, housekeepers, and students).
2.4. Statistical Analysis
All data for continuous variables are presented as means ± standard error (SE). Data for categorical
variables are presented as percentages ± SE. All sampling and weight variables were stratified. The SAS
survey was used for statistical analysis to account for the complex sampling design and to provide
nationally representative prevalence estimates. Analysis of variance (ANOVA) was used to compare
the mean values of the continuous variables, analysis of covariance (ANCOVA) was used to compare
the age-adjusted lipid level across the KNHANES phases, and the x2 test was used to compare
categorical variables. P for trend values were calculated among the KNHANES phases by logistic
regression analyses or linear regression after setting the phase as the continuous variable. We conducted
Bonferroni correction for multiple testing. Statistical analyses were performed using SAS version 9.4
(SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Characteristics of Sample
The unweighted sample sizes for this study in the KNHANES III (2005), IV (2007–2009),
V (2010–2012), and VI (2013–2015) were 24,752, 16,359, 17,243, and 15,536, respectively, and the
mean ages were 43.6, 44.8, 45.7, and 46.6 years, respectively (Table 1). The number and proportion of
women and men participating in the study were 13,251 (53.5%) and 11,501 (46.5%) in phase III, 9454
(57.8%) and 6905 (42.2%) in phase IV, 9994 (57.9%) and 7249 (42.1%) in phase V, and 8976 (57.8%) and
6560 (42.2%) in phase VI, respectively.
Table 2 describes the characteristics of participants after stratifying by sex and use of lipid-lowering
medications. Age significantly increased across the KNHANES phases. There were decreasing trends
in BMI in men and women with lipid-lowering medication use (β-coefficient = −0.354 and p for trend
< 0.001 in men, β-coefficient = −0.363 and p for trend < 0.001 in women). The level of BMI increased in
men without lipid-lowering medication use (β-coefficient = 0.107 and p for trend < 0.001), while BMI
showed no difference in women without lipid-lowering medication use over time.
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Table 1. Study population according to Korean National Health and Nutrition Examination Survey
(KNHANES) phase, age group, and sex.
Age Group III (2005) IV (2007–2009) V (2010–2012) VI (2013–2015)
Total, unweighted N 24752 16359 17243 15536
Age (years, mean ± SE) 43.6 ± 0.4 44.8 ± 0.3 45.7 ± 0.2 46.6 ± 0.2
Men, unweighted N (%) 11501 (46.5) 6905 (42.2) 7249 (42.1) 6560 (42.2)
Age (years, mean ± SE) 42.8 ± 0.4 43.8 ± 0.4 44.7 ± 0.3 45.5 ± 0.3
20–29 years (%) 21.7 (1.5) 20.2 (0.9) 19.0 (0.8) 18.7 (0.7)
30–39 years (%) 25.0 (1.4) 23.3 (0.9) 21.6 (0.7) 20.0 (0.7)
40–49 years (%) 23.8 (1.1) 23.4 (0.8) 23.0 (0.7) 21.6 (0.6)
50–59 years (%) 14.7 (0.9) 16.7 (0.6) 18.8 (0.6) 20.2 (0.6)
≥60 years (%) 14.9 (0.8) 16.3 (0.6) 17.5 (0.6) 19.6 (0.6)
Women, unweighted N (%) 13251 (53.5) 9454 (57.8) 9994 (57.9) 8976 (57.8)
Age (years, mean ± SE) 42.8 ± 0.4 43.8 ± 0.3 44.7 ± 0.3 45.5 ± 0.3
20–29 years (%) 20.5 (1.4) 18.4 (0.7) 17.0 (0.6) 15.9 (0.6)
30–39 years (%) 23.1 (1.1) 21.7 (0.7) 20.4 (0.6) 18.8 (0.6)
40–49 years (%) 22.3 (1.0) 22.1 (0.7) 21.6 (0.6) 21.1 (0.6)
50–59 years (%) 14.3 (0.7) 16.3 (0.5) 18.6 (0.5) 20.0 (0.5)
≥60 years (%) 19.9 (0.9) 21.4 (0.7) 22.6 (0.6) 24.2 (0.6)
All data are presented as mean ± standard error (SE) or percentage (SE).
3.2. Lipid Profiles
Table 3 shows the changes in mean lipid profile levels according to sex and age groups across
the KNHANES phases. The mean TC levels increased linearly from 183.4 mg/dL to 187.7 mg/dL
(β-coefficient = 1.331, p for trend < 0.001) in men, and from 184.3 mg/dL to 187.9 mg/dL (β-coefficient
= 0.805, p for trend = 0.002) in women. The mean HDL-C levels increased over the 11-year period in
both men and women (β-coefficient = 1.446, p for trend < 0.001 and β-coefficient = 2.308, p for trend <
0.001), respectively.
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Table 2. Participant characteristics according to KNHANES phase according to use of lipid-lowering medications.
With Lipid-lowering Medication
Men Women
KNHANES Phase III IV V VI III IV V VI
N (%) 110 (1.0) 175 (2.5) 380 (5.2) 437 (6.7) 177 (1.3) 349 (3.7) 686 (6.9) 889 (9.9)
Age (years) *,† 52.4 ± 1.9 55.5 ± 1.0 57.7 ± 0.7 58.8 ± 0.7 59.9 ± 1.2 60.7 ± 0.7 62.6 ± 0.5 63.5 ± 0.4
BMI (kg/m2) *,† 25.9 ± 0.4 25.8 ± 0.3 25.4 ± 0.2 25.0 ± 0.2 25.1 ± 0.3 25.8 ± 0.3 25.6 ± 0.2 24.9 ± 0.1
WC (cm) *,† 91.4 ± 2.7 90.1 ± 0.7 89.3 ± 0.6 88.1 ± 0.5 85.6 ± 0.8 86.7 ± 0.7 85.8 ± 0.6 83.8 ± 0.4
SBP (mmHg) *,† 131.8 ± 2.5 128.4 ± 1.6 124.9 ± 0.9 123.0 ± 0.7 124.9 ± 3.0 127.7 ± 1.0 128.5 ± 0.8 125.7 ± 0.7
DBP (mmHg) *,† 84.5 ± 1.5 83.3 ± 0.9 79.5 ± 0.6 77.0 ± 0.5 76.5 ± 1.7 79.6 ± 0.6 75.8 ± 0.5 74.5 ± 0.4
FPG (mg/dL) † 107.2 ± 3.4 112.2 ± 2.7 115.0 ± 2.1 111.9 ± 1.4 111.3 ± 5.2 109.6 ± 2.0 110.0 ± 1.8 107.9 ± 1.1
Monthly household income *,† 2650 ± 318 3647 ± 825 4737 ± 709 3851 ± 181 1814 ± 178 3732 ± 104.4 3520 ± 425 3005 ± 141
Occupation (%)
Office worker *,† 35.7 ± 10.3 32.0 ± 4.3 20.5 ± 2.7 24.7 ± 2.5 2.4 ± 0.2 4.5 ± 2.0 3.7 ± 1.0 6.6 ± 1.0
Manual worker *,† 45.0 ± 7.6 32.3 ± 4.1 46.2 ± 3.4 42.3 ± 2.8 27.2 ± 4.4 25.1 ± 3.0 26.5 ± 2.2 29.7 ± 1.8
Other† 19.3 ± 7.4 35.7 ± 4.1 33.3 ± 3.1 33.0 ± 2.7 70.4 ± 4.4 70.4 ± 3.2 70.0 ± 2.2 63.7 ± 1.9
Education duration (%)
<6 years† 21.4 ± 6.3 13.9 ± 2.7 22.0 ± 2.8 18.7 ± 2.1 63.0 ± 6.7 57.0 ± 3.5 60.1 ± 2.5 51.8 ± 2.1
6–8 years *,† 11.2 ± 4.6 20.6 ± 4.0 19.6 ± 2.6 14.9 ± 2.0 10.4 ± 4.7 15.8 ± 2.7 14.2 ± 1.7 15.0 ± 1.5
9–11 years † 48.4 ± 8.9 27.5 ± 3.9 32.9 ± 3.3 34.5 ± 2.9 17.0 ± 3.2 18.4 ± 2.5 20.1 ± 2.1 22.4 ± 1.6
≥12 years † 18.9 ± 7.8 37.9 ± 5.2 25.4 ± 2.8 31.9 ± 2.8 9.6 ± 4.2 8.8 ± 2.5 5.7 ± 1.1 10.9 ± 1.3
Without lipid-lowering medication
Men Women
KNHANES Phase III IV V VI III IV V VI
N (%) 11391 (99.0) 6730 (97.5) 6869 (94.8) 6123 (93.3) 13074 (96.3) 9105 (93.1) 9308 (93.1) 8087 (90.1)
Age (years) *,† 42.7 ± 0.4 43.5 ± 0.3 44.2 ± 0.3 44.9 ± 0.3 44.3 ± 0.4 45.4 ± 0.3 45.9 ± 0.3 46.3 ± 0.3
BMI (kg/m2) * 23.9 ± 0.1 24.0 ± 0.1 24.1 ± 0.1 24.3 ± 0.0 23.3 ± 0.1 23.2 ± 0.0 23.2 ± 0.1 23.1 ± 0.0
WC (cm) *,† 83.6 ± 0.3 84.2 ± 0.2 84.0 ± 0.2 84.7 ± 0.1 77.9 ± 0.3 78.3 ± 0.2 77.6 ± 0.2 77.4 ± 0.2
SBP (mmHg) 121.0 ± 0.4 119.0 ± 0.3 120.6 ± 0.3 119.1 ± 0.2 114.7 ± 0.5 113.4 ± 0.3 115.4 ± 0.3 113.4 ± 0.3
DBP (mmHg) *,† 80.2 ± 0.4 79.5 ± 0.2 79.4 ± 0.2 77.8 ± 0.2 74.1 ± 0.3 73.5 ± 0.2 73.7 ± 0.1 72.4 ± 0.2
FPG (mg/dL) *,† 95.2 ± 0.5 97.1 ± 0.4 97.9 ± 0.3 100.4 ± 0.3 92.1 ± 0.5 94.1 ± 0.3 94.1 ± 0.3 95.9 ± 0.3
Monthly household income *,† 2442 ± 58 3108 ± 86 4703 ± 186 3961 ± 66 2374 ± 64 2914 ± 74 4404 ± 136 3769 ± 62
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Table 2. Cont.
Without lipid-lowering medication
Men Women
KNHANES Phase III IV V VI III IV V VI
Occupation (%)
Office worker *,† 24.5 ± 1.3 28.1 ± 0.8 29.5 ± 0.8 31.4 ± 0.9 15.1 ± 1.0 17.3 ± 0.6 19.9 ± 0.6 22.9 ± 0.6
Manual worker * 52.1 ± 1.5 48.5 ± 0.9 50.0 ± 0.9 45.3 ± 0.9 30.6 ± 1.2 28.7 ± 0.7 32.8 ± 0.7 29.2 ± 0.7
Other † 23.4 ± 1.2 23.4 ± 0.8 20.4 ± 0.7 23.4 ± 0.7 54.4 ± 1.3 53.9 ± 0.8 47.3 ± 0.7 47.9 ± 0.7
Education duration (%)
<6 years *,† 11.8 ± 0.7 13.2 ± 0.6 11.6 ± 0.5 11.0 ± 0.5 26.0 ± 1.2 25.9 ± 0.8 23.6 ± 0.7 19.5 ± 0.7
6–8 years *,† 9.8 ± 0.7 10.3 ± 0.5 10.0 ± 0.5 8.4 ± 0.4 11.0 ± 0.7 10.4 ± 0.4 9.8 ± 0.4 9.1 ± 0.4
9–11 years *,† 43.3 ± 1.5 41.4 ± 1.0 41.2 ± 0.8 40.2 ± 0.9 38.1 ± 1.2 37.7 ± 0.8 35.8 ± 0.7 35.6 ± 0.7
≥12 years † 35.1 ± 1.5 35.1 ± 1.0 37.2 ± 0.9 40.4 ± 0.9 24.9 ± 1.4 26.0 ± 0.8 30.7 ± 0.8 35.8 ± 0.8
p for trend were determined by linear regression analysis with weighting of survey design. Age, BMI, WC, SBP, DBP, FPG, and monthly household income were presented as continuous
values, and occupation and education level were presented as categorical values. Monthly household income: total monthly house income/rooted value of number of family members,
1 USD = 1000 Korean won. Occupation: office worker (general managers, government administrators, professionals, and office workers); manual worker (clerks, service and sales workers,
skilled agricultural, forestry, and fishery workers, persons who operate or assemble craft, equipment, or machines, and elementary workers); other (unemployed persons, housekeepers,
and students). Abbreviations: KNHANES: Korean National Health and Nutrition Examination Survey; BMI: body mass index; WC: waist circumference; SBP: systolic blood pressure; DBP:
diastolic blood pressure; FPG: fasting plasma glucose. III: 2005, IV: 2007–2009, V: 2010–2012, VI: 2013–2015. Bonferroni correction for multiple testing was conducted; * p for trend < 0.0125
in men, † p for trend < 0.0125 in women.
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Table 3. Trends of age-adjusted and age-specific mean lipid profiles according to sex.
KNHANES Phase Men Women
III IV V VI III IV V VI
TC (mg/dL)
Age-adjusted **‡ 183.4 ± 0.9 185.5 ± 0.6 187.5 ± 0.6 187.7 ± 0.5 184.3 ± 0.7 187.7 ± 0.5 188.7 ± 0.5 187.9 ± 0.5
20–29 years ‡ 173.3 ± 2.3 171.8 ± 1.4 174.6 ± 1.6 174.4 ± 1.2 165.4 ± 1.7 170.2 ± 1.2 170.5 ± 1.1 173.7 ± 1.0
30–39 years **‡ 183.3 ± 1.7 188.0 ± 1.0 192.7 ± 1.1 193.6 ± 1.3 172.8 ± 1.4 175.7 ± 0.8 179.8 ± 1.0 180.1 ± 0.8
40–49 years ‡ 191.7 ± 1.8 194.8 ± 1.2 194.1 ± 1.1 197.1 ± 1.1 183.3 ± 1.4 185.4 ± 0.8 189.0 ± 1.0 189.1 ± 0.9
50–59 years 187.3 ± 1.8 189.6 ± 1.3 193.2 ± 1.3 191.2 ± 1.1 200.4 ± 2.0 203.6 ± 1.3 205.1 ± 1.1 202.2 ± 0.9
60+ years ‡ 183.1 ± 1.8 183.5 ± 1.1 182.9 ± 0.9 181.8 ± 0.9 200.2 ± 1.5 203.6 ± 1.1 198.9 ± 0.8 195.4 ± 0.9
HDL-C (mg/dL)
Age-adjusted **‡ 42.4 ± 0.3 45.5 ± 0.2 46.9 ± 0.2 47.6 ± 0.2 47.3 ± 0.3 50.7 ± 0.2 52.7 ± 0.2 54.8 ± 0.2
20–29 years ‡ 44.5 ± 0.7 47.5 ± 0.4 48.7 ± 0.5 50.2 ± 0.4 49.7 ± 0.6 55.0 ± 0.4 56.2 ± 0.5 58.5 ± 0.4
30–39 years ‡ 41.7 ± 0.4 44.7 ± 0.3 46.9 ± 0.4 47.4 ± 0.4 48.5 ± 0.5 51.7 ± 0.3 54.7 ± 0.4 56.6 ± 0.4
40–49 years ‡ 42.0 ± 0.5 45.6 ± 0.4 46.0 ± 0.3 46.9 ± 0.4 47.3 ± 0.5 50.5 ± 0.3 52.4 ± 0.3 55.2 ± 0.3
50–59 years ‡ 40.8 ± 0.6 45.1 ± 0.3 46.4 ± 0.4 46.7 ± 0.3 46.7 ± 0.6 49.9 ± 0.3 51.8 ± 0.3 53.8 ± 0.3
60+ years ‡ 43.1 ± 0.6 44.6 ± 0.3 46.5 ± 0.3 46.7 ± 0.3 44.5 ± 0.4 46.5 ± 0.3 48.5 ± 0.3 50.0 ± 0.3
TG (mg/dL)
Age-adjusted **‡ 155.7 ± 3.6 152.9 ± 1.7 154.4 ± 2.0 163.5 ± 2.0 113.4 ± 1.5 113.6 ± 1.1 111.6 ± 1.2 109.3 ± 1.0
20–29 years 113.6 ± 5.5 120.3 ± 2.9 117.0 ± 4.3 120.5 ± 3.8 85.1 ± 2.6 84.1 ± 2.2 81.8 ± 1.8 81.4 ± 2.0
30–39 years 158.6 ± 8.2 156.3 ± 3.4 156.3 ± 4.0 176.2 ± 5.2 93.2 ± 2.3 94.1 ± 1.8 94.7 ± 2.2 94.7 ± 2.2
40–49 years 183.9 ± 8.6 177.4 ± 4.3 176.1 ± 4.9 150.2 ± 1.1 111.1 ± 3.4 109.7 ± 1.8 112.1 ± 4.1 106.2 ± 1.9
50–59 years 183.7 ± 9.2 166.8 ± 4.3 182.1 ± 5.2 179.1 ± 4.8 135.1 ± 5.5 131.7 ± 2.6 128.8 ± 2.4 129.0 ± 2.6
60+ years ‡ 140.6 ± 5.0 143.9 ± 2.7 142.2 ± 2.5 146.7 ± 2.9 143.5 ± 3.6 148.7 ± 2.4 140.4 ± 1.8 136.0 ± 1.8
Non-HDL-C (mg/dL)
Age-adjusted ‡ 141.1 ± 0.8 140.0 ± 0.6 140.6 ± 0.6 140.0 ± 0.5 137.0 ± 0.7 136.9 ± 0.5 136.0 ± 0.4 133.1 ± 0.4
20–29 years 128.9 ± 2.2 124.3 ± 1.4 125.9 ± 1.6 124.3 ± 1.3 115.7 ± 1.5 115.2 ± 1.1 114.3 ± 1.0 115.2 ± 1.0
30–39 years 141.6 ± 1.6 143.3 ± 1.0 145.8 ± 1.2 146.1 ± 1.3 124.3 ± 1.2 124.0 ± 0.8 125.2 ± 0.9 123.5 ± 0.8
40–49 years 149.7 ± 1.7 149.2 ± 1.2 148.1 ± 1.1 150.2 ± 1.1 135.9 ± 1.2 134.8 ± 0.8 136.6 ± 1.0 133.9 ± 0.9
50–59 years ‡ 146.5 ± 1.8 144.5 ± 1.3 146.8 ± 1.3 144.5 ± 1.2 153.6 ± 1.9 153.8 ± 1.2 153.3 ± 1.0 148.4 ± 0.9
60+ years **‡ 140.0 ± 1.8 139.0 ± 1.1 136.4 ± 0.8 135.2 ± 0.9 155.7 ± 1.5 157.1 ± 1.1 150.4 ± 0.8 145.4 ± 0.9
p for trend were determined by linear regression analysis with weighting of survey design. Abbreviations: KNHANES: Korean National Health and Nutrition Examination Survey; TC:
total cholesterol; HDL-C: high-density lipoprotein-cholesterol; TG: triglyceride. III: 2005, IV: 2007–2009, V: 2010–2012, VI: 2013–2015. Bonferroni correction for multiple testing was
conducted; ** p for trend < 0.00417 in men, ‡ p for trend < 0.00417 in women.
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3.3. Lipid-lowering Medications
Figure 1 presents the age-adjusted and age-specific proportion of those taking lipid-lowering
medications across the KNHANES phases. For KNHANES III–VI (2005 and 2007–2015), the proportion
of participants on lipid-lowering medication increased from 1.6 to 4.7% in men (β-coefficient = 0.414,
p for trend < 0.001) (Figure 1A) and from 1.5 to 7% in women (β-coefficient = 0.531, p for trend < 0.001)
(Figure 1B). This trend was apparent in age groups over 40 years in both men and women.
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(B) women. p-values for trends wer dete min d by logistic regressio analyses after setti g the
KNHANES phase as the continuous variable. KNHANES: Korean National Health and Nutrition
Examination Survey.
3.4. Lipid Profile According to Treatment of Lipid Lowering Drug
To clarify the effect of lipid-lowering medications, we also investigated lipid profile trends in
participants after stratifying by use of lipid-lowering drugs (Table 4). The mean TC and non-HDL- C
levels declined in men with lipid-lowering drug use (TC: 195.7 to 174.6 mg/dL, p for trend < 0.001;
non-HDL-C: 240.4 to 213.0 mg/dL, p for trend < 0.001) over time. Mean TC and TG levels increased
in men without lipid-lowering drug use (TC: 183.6 to 188.9 mg/dL, p for trend < 0.001; TG: 155.0 to
162.8 mg/dL, p for trend = 0.002). In women with lipid-lowering drug use, all lipid profiles levels,
except HDL-C, decreased over time. TC was significantly elevated in women without lipid-lowering
drug use (TC: 184.4 to 190.1 mg/dL, p for trend < 0.001), while other lipid profiles (TG and non-HDL-C)
decreased during the same time period.
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Table 4. Trends of age-adjusted estimated lipid levels with or without use of lipid-lowering medication
according to sex.
KNHANES Phase III IV V VI P value β-coefficient P for Trend
Men
With use of lipid-lowering medication
TC (mg/dL) 195.7 ± 3.0 185.7 ± 0.1 183.2 ± 0.1 174.6 ± 0.1 <0.001 −6.260 <0.001
TG (mg/dL) 240.4 ± 18.5 209.5 ± 0.6 220.6 ± 0.8 213.0 ± 1.0 <0.001 −2.173 0.558
HDL-C (mg/dL) 38.2 ± 0.6 43.6 ± 0.0 44.0 ± 0.0 45.4 ± 0.0 <0.001 1.431 <0.001
Non-HDL-C (mg/dL) 157.5 ± 3.1 142.1 ± 0.1 139.2 ± 0.1 129.1 ± 0.1 <0.001 −7.691 <0.001
Without use of lipid-lowering medication
TC (mg/dL) 183.6 ± 0.9 185.8 ± 0.6 188.2 ± 0.6 188.9 ± 0.5 <0.001 1.735 <0.001
TG (mg/dL) 155.0 ± 3.6 152.3 ± 1.6 153.2 ± 2.1 162.8 ± 2.1 0.004 3.446 0.004
HDL-C (mg/dL) 42.4 ± 0.3 45.5 ± 0.2 46.9 ± 0.2 47.6 ± 0.2 <0.001 1.451 <0.001
Non-HDL-C (mg/dL) 141.2 ± 0.8 140.3 ± 0.6 141.3 ± 0.6 141.3 ± 0.5 ns 0.282 ns
Women
With use of lipid-lowering medication
TC (mg/dL) 195.2 ± 2.4 184.9 ± 0.0 175.4 ± 0.0 172.0 ± 0.0 <0.001 −6.331 <0.001
TG (mg/dL) 172.6 ± 7.7 153.2 ± 0.0 139.3 ± 0.1 136.0 ± 0.1 <0.001 −8.775 <0.001
HDL-C (mg/dL) 46.1 ± 1.2 50.9 ± 0.0 51.8 ± 0.0 54.7 ± 0.0 <0.001 2.224 <0.001
Non-HDL-C (mg/dL) 149.1 ± 1.8 133.9 ± 0.0 123.6 ± 0.0 117.4 ± 0.0 <0.001 −8.555 <0.001
Without use of lipid-lowering medication
TC (mg/dL) 184.4 ± 0.7 188.1 ± 0.5 190.0 ± 0.5 190.1 0.5 <0.001 1.593 <0.001
TG (mg/dL) 112.9 ± 1.5 113.1 ± 1.1 111.4 ± 1.1 109.2 1.0 ns −1.520 0.010
HDL-C (mg/dL) 47.3 ± 0.2 50.7 ± 0.2 52.7 ± 0.2 54.8 0.2 <0.001 2.300 <0.001
Non-HDL-C (mg/dL) 137.1 ± 0.7 137.4 ± 0.5 137.3 ± 0.4 135.3 0.4 0.012 −0.708 0.006
P for trend were determined by age-adjusted linear regression analysis with weighting of survey design. Abbreviations:
KNHANES: Korean National Health and Nutrition Examination Survey; TC: total cholesterol; HDL-C: high-density
lipoprotein-cholesterol; TG: triglyceride; NS: no significance. III: 2005, IV: 2007–2009, V: 2010–2012, VI: 2013–2015.
Bonferroni correction for multiple testing was conducted; significant p-value < 0.0125 and p-for trend < 0.0125.
Figure 2 presents the age-adjusted prevalence of hypercholesterolemia (A), hypertriglyceridemia
(B), and hypo-HDL-cholesterolemia (C) in participants without lipid-lowering medication use.
There was an increasing trend in hypercholesterolemia in men (β-coefficient = 0.123 and p for
trend < 0.001) over the examination cycles. By contrast, the prevalence of hypercholesterolemia was
not significantly different, and the prevalence of hypertriglyceridemia slightly decreased over time
(β-coefficient = −0.064 and p for trend < 0.001) in women. There were significant downward trends in
the prevalence of hypo-HDL-cholesterolemia in both men and women (β-coefficient = −0.281 for men,
−0.224 for women, and p for trend < 0.001 in both sexes) over the time course of the study period.Int. J. Environ. Res. Public Health 2019, 16, x FOR PEER REVIEW 11 of 16 
 
 
Figure 2. Trends in age-adjusted prevalence of hypercholesterolemia, hypertriglyceridemia, and 
hypo-HDL-cholesterolemia in subjects with no use of lipid-lowering medication. (A) 
Hypercholesterolemia. (B) Hypertriglyceridemia. (C) Hypo-HDL-cholesterolemia. P-values for 
trends were determined by logistic regression analyses after setting the KNHANES phase as the 
continuous variable. KNHANES: Korean National Health and Nutrition Examination Survey. 
In age-specific hypercholesterolemia, the prevalence of hypercholesterolemia significantly 
increased in the age groups of 30–59 and 30–49 years in men and women, respectively, without lipid-
lowering medication use (Figure 3a). The prevalence of hypertriglyceridemia was not significantly 
different in all age groups in men and women (Figure 3b). The prevalence of hypo-HDL 
cholesterolemia significantly decreased in all age groups of men and women (Figure 3c). 
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Korean National Health and Nutrition Examination Survey.
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In age-specific hypercholesterolemia, the prevalence of hypercholesterolemia significantly
increased in the age groups of 30–59 and 30–49 years in men and women, respectively, without
lipid-lowering medication use (Figure 3a). The prevalence of hypertriglyceridemia was not significantly
different in all age groups in men and women (Figure 3b). The prevalence of hypo-HDL cholesterolemia
significantly decreased in all age groups of men and women (Figure 3c).
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4. Discussion
Our data revealed that TC and HDL-C level increased and the proportion of taking lipid-lowering
medications increased over the 11-year study period.
Many clinical and epidemiologic studies have demonstrated that dyslipidemia is an important risk
factor of CVD [6,18,19]. Therefore, many health authorities, including those in Korea, have conducted
national health screening programs for early detection and management of dyslipidemia [20,21].
The National Cholesterol Expert Panel (NCEP) suggests screening for dyslipidemia in adults over
20 years of age [22], while the United States Preventive Services Task Force (USPSTF) provides positive
evidence for screening dyslipidemia in adults [23]. Based on standard guidelines, expert groups also
recommend active management, such as therapeutic lifestyle modification and use of appropriate
medications (such as statins) in patients with dyslipidemia [21,22,24].
In this study, we determined that the proportion of adults on lipid-lowering drugs gradually
increased over the course of KNHANES phases III–VI, and that the proportion of participants on
lipid-lowering medication was higher in women than men. Depending on the use of lipid-lowering
drug, the lipid profile in participants taking lipid-lowering medications improved, with decreasing TC,
non-HDL-C, and TG and increasing HDL-C levels in both men and women. Meanwhile, TC increased in
participants who were not taking lipid-lowering drugs. HDL-C level consistently increased regardless
of sex, age, and use of lipid-lowering drug. Age-specific analysis revealed an upward trend in TC that
was significant in the 30–59 years age group in men and the 30–49 years age group in women without
lipid-lowering medication use. The level of lipid-lowering drug usage did not increase significantly in
the relatively younger age groups.
Our findings are in agreement with several previous studies. Several studies identified the
increasing trend of TC in Japan, Turkey, and China [10–12]. Meanwhile, a recent Japanese study
reported that serum HDL-C continues to increase using the National Health and Nutrition Survey [25].
A study conducted in a Canadian province also revealed a significant downward trend in the prevalence
of hypo-HDL-cholesterolemia over a six-year period [26]. There is no exact reason to explain such
trends. HDL-C levels are affected not only by genetic factors, but also by socioeconomic status (i.e.,
education level, economic level, and occupation) [27].
High socioeconomic status has been regarded as a key determinant of medical intervention
accessibility and exposure to modifiable risk factors [28]. The Global Burden of Disease (GBD) 2015
study reported that the prevalence of CVD has declined in regions with a high socioeconomic index
(including per capita income and education level) [28]. Korea is one of the most developed countries
in Asia, and both household incomes and education levels have improved between 2005 and 2015.
Favorable changes in socioeconomic status may lead to increased HDL-C levels.
TG in women without anti-dyslipidemic use has declined. The differences in TG trends between
men and women may partly be explained by different rates of obesity between the sexes. According to
our previous study on obesity trends, male obesity has increased with time, while female obesity has
leveled off, or even decreased [29]. Different trends in obesity prevalence between men and women may
also subsequently lead to variable lipid profiles in participants who are not taking lipid-lowering drugs.
TC level has been increasing in adults (30–59 years) not taking lipid-lowering medication.
These results suggest that more active and practical interventions are needed to prevent and manage
dyslipidemia in these age groups. Screening obese individuals and those with unhealthy lifestyles
should be the first step to prevent dyslipidemia and reduce future CVD events [30–32]. Many individuals
are unaware that they have dyslipidemia. Although the awareness rate of dyslipidemia varies
according to prior studies, one recent Korean study reported that only approximately 17% of adults
with dyslipidemia over 20 years old were aware of their dyslipidemia status [33]. Effective medical
therapy, such as administration of statin drugs, helps to prevent CVD [34,35]. However, recent studies
suggested that chronic inflammation is a key risk factor of CVD [36]. Therefore, reducing inflammation
manifestation by lifestyle modifications, such as increasing physical activity, adopting healthy diet,
and maintaining a healthy body weight, must also be emphasized [4,36].
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This study had several limitations. First, we did not include the low-density lipoprotein cholesterol
(LDL-C) levels because they were not directly measured in KNHANES. Although LDL-C levels
estimated by the Friedwald equation were correlated with direct measurement, underestimation of
the LDL-C level is an important problem to evaluate the high-risk group in the presence of TG ≥
150 mg/dL [37]. Therefore, we did not include LDL levels to minimize bias. Alternatively, we considered
non-HDL cholesterol. Several studies supported that non-HDL-C could be a more reliable predictor for
CVD [38,39]. Second, we did not distinguish between the types of lipid-lowering medications used by
patients. Different drug classes (such as statins, fibric acid, and niacin) have variable effects on specific
lipid levels, and in particular on HDL-C [40]. Therefore, the HDL-C level may have been influenced by
the type of drug used. Furthermore, we could not consider HDL functionality. Emerging evidence
established that HDL functionality is more important than quantity, and HDL-C may no longer be a
reliable marker [41,42]. Our authors believe that there is a need to develop inexpensive methods to
evaluate functionality of HDL using a large population-based study. Finally, there could have been
bias deriving from unequal sex ratio.
Despite these limitations, our study has several advantages. First, we applied sampling weights
to all analyses to represent the average Korean citizen. Second, this study investigated an 11-year trend
of lipid profiles using nationally representative data. Finally, we examined the lipid profile trend in
patients who were and were not treated with lipid-lowering medications.
5. Conclusions
The analyses identified an upward trend in TC and HDL-C over the 11-year period. There was
also an increase in the use of lipid-lowering drugs over time. The positive trends in TC level were
only seen in adults who used lipid-lowering drugs. We must continually monitor how long these
trends continue, and what type of changes occur. Furthermore, more active strategies for lifestyle
changes, as well as more intense screening and treatment of dyslipidemia, remain very important in
the reduction of CVD risk in Korean adults.
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